Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma pharmacokinetics of once- versus twice-daily abacavir and lamivudine in HIV-infected infants and young children
2005-004433-18Phase 4Completed
- Sponsor
- Penta Foundation
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of abacavir and lamivudine in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Penta Foundation. Primary endpoints: Abacavir AUC after once- vs twice-daily dosing, Abacavir Cmin after once- vs twice-daily dosing and 4 more. Started Dec 2005; status: completed.
02
Drugs
abacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-004433-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004433-18.